Noden is a Dublin-headquartered global specialty pharmaceutical company, focused on providing unique, complex to manufacture prescription medicines in the cardiovascular space for patients who are intolerant to mainstream treatments
SCP's proprietary research identified Noden Pharma as a strong target to invest in the specialty pharma sector. Stanley acquired Noden as a platform for a strategy to consolidate the mature-product specialty pharma marketplace.
SCP worked alongside Noden's management team to execute on organic value creation and an identified M&A pipeline. Under SCP's ownership, Noden Pharma has gone through significant optimization initiatives including cost base restructuring, SKUs rationalization, and identification of geographies to be discontinued leading to broad operational efficiencies. The business was exited successfully in September 2022